Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Wiener Neustadt – page 42

861 clinical trials in Wiener Neustadt, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Wiener Neustadt at a glance
861
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

861 trials in Wiener Neustadt

Open in trial search

A Study of Ianalumab and Eltrombopag for Patients with Primary Immune Thrombocytopenia Who Did Not Respond Well to or Relapsed After Steroid Treatment

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Eltrombopag
  • Sponsor:Novartis Pharma AG

Dermatitis atopic

Not recruiting

Study of Rocatinlimab with Topical Treatments for Adults with Moderate to Severe Atopic Dermatitis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Breast cancer+1

Not recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of zoldonrasib in patients with RAS G12D mutation non-small cell lung cancer who have received previous treatment

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Zoldonrasib
  • Sponsor:Revolution Medicines Inc.

Colitis ulcerative

Not recruiting

Study of efavaleukin alfa safety and effectiveness in adults with moderate to severe ulcerative colitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Colitis ulcerative

Not recruiting

Study of Efavaleukin Alfa to Treat Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Study of JSB462 and lutetium (177Lu) vipivotide tetraxetan combination for adult men with PSMA-positive metastatic castration resistant prostate cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Novartis Pharma AG

Arteriosclerosis

Not recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Colitis ulcerative

Not recruiting

Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Study on the Effectiveness and Safety of EYE103 Compared to Ranibizumab for Patients with Diabetic Macular Edema

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:EYE103
  • Sponsor:Eyebiotech Limited

Renal transplant+1

Not recruiting

Study of Ravulizumab to Prevent Delayed Graft Function in Adult Patients After Kidney Transplant

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Wiener Neustadt

What the registry says about research in the country

01 Oncology - Digestive System

Groundbreaking research focusing on colorectal cancer treatments, including studies evaluating new combination therapies with immunotherapy agents. Investigations target both MSS/pMMR and KRAS G12C mutations.

  • Metastatic Colorectal Cancer
  • Gastric Cancer
  • Cholangiocarcinoma

Novel therapeutic approaches combining targeted treatments with established protocols.

02 Hematologic Malignancies

Advanced studies in blood cancers, particularly focusing on multiple myeloma and follicular lymphoma. Research includes innovative combination therapies and comparative effectiveness studies.

  • Multiple Myeloma Treatments
  • Lymphoma Therapies
  • Blood Disorders

Emphasis on improving outcomes for newly diagnosed patients and those requiring alternative treatment options.

03 Breast Cancer Research

Innovative trials examining treatments for HER2-negative breast cancer, including studies of new therapeutic agents and combination approaches for both early-stage and metastatic disease.

  • ER+ Breast Cancer
  • Metastatic Disease
  • Adjuvant Therapies

Focus on personalized treatment strategies and targeted therapies.

04 Multi-Cancer Approaches

Comprehensive research involving multiple cancer types, including solid tumors across various organs. Studies evaluate novel therapeutic combinations and immunotherapy approaches.

  • Bladder Cancer
  • Lung Cancer
  • Pancreatic Cancer

Integration of innovative treatment modalities across different cancer types.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.